

Relvar Ellipta (Fluticasone, Vilanterol)

【TREL2】Relvar[®] Ellipta[®] Inhalation 184/22mcg/Dose

ATC Code : R03AK10

中文名：潤娃易利達 184/22 mcg 乾粉吸入劑 «GSK»

適應症：氣喘的治療：治療適合使用吸入型皮質類固醇及長效 β 2 作用劑合併治療的 18 歲及以上氣喘患者。

主要成分： Each dose contains:
Fluticasone 184mcg, Vilanterol 22mcg

藥理分類： Corticosteroid, Inhalant; Beta2-Adrenergic Agonist, Long-Acting.

用法用量： Adult (\geq 18 yrs), 1 dose QD

Safety and efficacy not established in children $<$ 18 yrs

不良反應： 震顫、心悸、頭痛、聲音嘶啞、口咽念珠菌感染。

注意事項： 1.每天於同一時間使用，每天一次。
2.尚未準備好吸入藥劑時，請勿將吸口蓋打開，若吸口蓋打開即已上藥。如果您將吸口蓋打開再關上，但又未吸入藥物，您會浪費掉該劑藥物。該劑浪費掉的藥物會被密封在吸入器內部，但沒辦法再供使用。
3.吸入之後應用水漱口，且不可吞下，這是為了幫助降低發生口咽念珠菌病的風險。

懷 孕 期： 1.目前並無足夠 Relvar[®] Ellipta[®] 使用於懷孕婦女的臨床經驗。
2.在懷孕期間，除非於評估後治療的益處高於可能的風險，才能使用。
3. Adverse events have not been observed in animal reproduction studies.
4.Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during pregnancy (refer to the fluticasone, oral inhalation monograph for additional details).
5.Beta-agonists have the potential to affect uterine contractility if administered during labor.

授 乳 期： 1.目前並不確知 fluticasone 或 vilanterol 是否會分泌進入人類乳汁。不過，有其他的皮質類固醇與 β 2 作用劑曾在人類的乳汁中檢出。因此，對授乳母親投予本藥時應謹慎。
2. It is not known if sufficient quantities of fluticasone or vilanterol are absorbed following inhalation to produce detectable amounts in breast milk.
3. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

給付規定： 全民健保藥品給付規定：
依「成人呼吸道疾患吸入製劑給付規定表」及「兒童呼吸道疾患吸入製劑給付規定表」規定辦理。